Regulatory T cell levels in migraine: A systematic review and meta-analysis.

IF 8.7 1区医学 Q1 CLINICAL NEUROLOGY

Journal of Headache and Pain Pub Date : 2026-07-16 DOI:10.1186/s10194-026-02443-7

Emily Stuchfield-Denby, Samuel Adelou, Xavier Moisset, Radhouane Dallel

{"title":"Regulatory T cell levels in migraine: A systematic review and meta-analysis.","authors":"Emily Stuchfield-Denby, Samuel Adelou, Xavier Moisset, Radhouane Dallel","doi":"10.1186/s10194-026-02443-7","DOIUrl":null,"url":null,"abstract":"Background: Although recent research suggests that regulatory T (Treg) cells may be involved in migraine pathophysiology, no review has provided a comprehensive assessment of their levels in this condition. This systematic review and meta-analysis aims to assess Treg levels in migraine patients.Methods: We systematically searched PubMed, Embase and Cochrane on July 5, 2024 (updated on March 19, 2026), and included all original studies providing data on Treg levels in migraine.Results: Among 1,162 studies identified, five were included in the narrative review and four in the meta-analysis. Data were pooled using a random-effects model. Standardized mean differences (SMD) were calculated to compare peripheral whole blood Treg levels between migraine and control groups. Our narrative review showed decreased Treg levels in three of five studies comparing migraine patients and controls, and in two of three studies on interictal episodic migraine patients and controls. Our meta-analysis of few but carefully selected data suggested a significant decrease in Treg cell levels in migraine (SMD - 4.21 [-7.76; -0.66], p = 0.02, I²=98.3%).Conclusions: Our findings suggest Treg levels are decreased in migraine and of potential interest in understanding migraine pathophysiology. However, the limited data available warrant further investigations to shed light on their relevance and therapeutic potential in this condition.Trial registration: PROSPERO CRD42023490445.Clinical trial number: Not applicable.","PeriodicalId":16013,"journal":{"name":"Journal of Headache and Pain","volume":" ","pages":""},"PeriodicalIF":8.7000,"publicationDate":"2026-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13656507/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Headache and Pain","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s10194-026-02443-7","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Although recent research suggests that regulatory T (Treg) cells may be involved in migraine pathophysiology, no review has provided a comprehensive assessment of their levels in this condition. This systematic review and meta-analysis aims to assess Treg levels in migraine patients.

Methods: We systematically searched PubMed, Embase and Cochrane on July 5, 2024 (updated on March 19, 2026), and included all original studies providing data on Treg levels in migraine.

Results: Among 1,162 studies identified, five were included in the narrative review and four in the meta-analysis. Data were pooled using a random-effects model. Standardized mean differences (SMD) were calculated to compare peripheral whole blood Treg levels between migraine and control groups. Our narrative review showed decreased Treg levels in three of five studies comparing migraine patients and controls, and in two of three studies on interictal episodic migraine patients and controls. Our meta-analysis of few but carefully selected data suggested a significant decrease in Treg cell levels in migraine (SMD - 4.21 [-7.76; -0.66], p = 0.02, I²=98.3%).

Conclusions: Our findings suggest Treg levels are decreased in migraine and of potential interest in understanding migraine pathophysiology. However, the limited data available warrant further investigations to shed light on their relevance and therapeutic potential in this condition.

Trial registration: PROSPERO CRD42023490445.

Clinical trial number: Not applicable.

查看原文本刊更多论文

偏头痛的调节性T细胞水平：系统回顾和荟萃分析。

背景：尽管最近的研究表明调节性T （Treg）细胞可能参与偏头痛的病理生理，但尚未有综述对其在这种情况下的水平进行全面评估。本系统综述和荟萃分析旨在评估偏头痛患者的Treg水平。方法：我们于2024年7月5日系统检索PubMed， Embase和Cochrane（更新于2026年3月19日），并纳入所有提供偏头痛Treg水平数据的原始研究。结果：在鉴定的1162项研究中，5项纳入叙述性综述，4项纳入meta分析。数据采用随机效应模型汇总。计算标准化平均差异（SMD）来比较偏头痛组和对照组的外周血Treg水平。我们的叙述性回顾显示，在比较偏头痛患者和对照组的五项研究中，有三项研究的Treg水平下降，在间歇发作性偏头痛患者和对照组的三项研究中，有两项研究的Treg水平下降。我们对少数但精心挑选的数据进行荟萃分析，发现偏头痛患者Treg细胞水平显著降低（SMD - 4.21 [-7.76; -0.66], p = 0.02, I²=98.3%）。结论：我们的研究结果表明，Treg水平在偏头痛中降低，这对了解偏头痛的病理生理有潜在的意义。然而，有限的可用数据需要进一步调查，以阐明其相关性和治疗潜力。试验注册：PROSPERO CRD42023490445。临床试验号：不适用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Headache and Pain 医学-临床神经学

CiteScore

11.80

自引率

13.50%

发文量

143

审稿时长

6-12 weeks

期刊介绍： The Journal of Headache and Pain, a peer-reviewed open-access journal published under the BMC brand, a part of Springer Nature, is dedicated to researchers engaged in all facets of headache and related pain syndromes. It encompasses epidemiology, public health, basic science, translational medicine, clinical trials, and real-world data. With a multidisciplinary approach, The Journal of Headache and Pain addresses headache medicine and related pain syndromes across all medical disciplines. It particularly encourages submissions in clinical, translational, and basic science fields, focusing on pain management, genetics, neurology, and internal medicine. The journal publishes research articles, reviews, letters to the Editor, as well as consensus articles and guidelines, aimed at promoting best practices in managing patients with headaches and related pain.